AlzeCure Pharma secures €2.5M grant from EIC Accelerator
AlzeCure Pharma Secures €2.5 Million Grant from EIC Accelerator with Potential for Additional Equity Financing to Advance Breakthrough Alzheimer’s Treatment
AlzeCure Pharma, a Swedish clinical-stage pharma company specializing in innovative treatments for central nervous system (CNS) disorders, has been awarded a €2.5 million grant from the European Innovation Council (EIC) Accelerator under the Horizon Europe program. In addition, the company has the potential to receive additional equity financing through the EIC Fund, subject to further due diligence and conditions being met. This funding represents a significant milestone in the company’s mission to bring disease-modifying therapies for Alzheimer’s disease (AD) to market.
AlzeCure’s lead drug candidate, ACD856, represents a paradigm shift in Alzheimer’s treatment. Unlike existing therapies that offer only symptomatic relief, ACD856 enhances neurotrophic signaling pathways, including Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), which are essential for maintaining neuronal health and cognitive function. The drug has demonstrated an excellent safety profile in Phase I trials and is designed for oral administration, ensuring patient accessibility.The EIC Accelerator funding will enable AlzeCure to advance ACD856 into a Phase II clinical trial, which aims to validate its efficacy and further optimize GMP manufacturing processes. This study will be a critical step toward securing an out-licensing agreement with a major pharmaceutical partner, accelerating the path to commercialization.Alzheimer’s disease remains one of the most pressing global health challenges, with its prevalence expected to nearly double by 2050. Current treatments offer only temporary cognitive improvements, leaving an urgent need for disease-modifying therapies. ACD856’s dual action—providing both symptomatic relief and disease modification—positions it as a potential game-changer in the AD treatment landscape.
Martin Jönsson, CEO of AlzeCure Pharma, commented: "We are honored to receive this prestigious funding from the EIC Accelerator, which recognizes ACD856's groundbreaking potential. This support will accelerate our clinical development and bring us closer to delivering a transformative therapy for Alzheimer's patients. The expertise and dedication of GAEU Consulting were instrumental in securing this highly competitive funding, guiding us through the intricate application process with unparalleled professionalism. Their strategic approach and deep knowledge of the EIC Accelerator framework have been invaluable, and we highly recommend GAEU Consulting to any company seeking to navigate the complexities of European funding opportunities."
Tomasz Wąsik, MBA, CEO of GAEU Consulting Horizon Europe Centre of Excellence, stated: "Winning the EIC Accelerator grant is an outstanding achievement, and AlzeCure’s success demonstrates the transformative potential of ACD856. At GAEU Consulting, we take pride in our deep expertise spanning science, business strategy, and financial structuring. Our team of specialists provided comprehensive support, ensuring that AlzeCure’s application met the highest standards of clinical viability, commercial potential, and investor appeal. By integrating scientific rigor with financial and strategic excellence, we have successfully positioned AlzeCure for this pivotal milestone."
AlzeCure’s work aligns with the European Union’s priorities under the European Health Union initiative, which seeks to address critical healthcare challenges. ACD856 has the potential to significantly reduce the burden of Alzheimer’s disease by improving patient outcomes, lowering long-term healthcare costs, and reinforcing Europe’s leadership in cutting-edge neuroscience research. This latest funding marks a pivotal step for AlzeCure Pharma as it advances toward delivering a first-in-class, disease-modifying therapy that could redefine Alzheimer’s treatment and improve the lives of millions worldwide.
